14th EANO Annual Meeting 2019
September 19-22, 2019
Lyon, France
Representatives:
Juergen Gamer, Ph.D., VP Business Development
Ulrike Jaegle, Ph.D., VP Regulatory Affairs
Andriy Krendyukov, M.D., MBA, VP Medical Affairs
Christian Merz, Ph.D., Head of Cellular Analytics
Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment
Poster Presentation on September 21, 3:45-5:15 pm (Poster Session 2):
"Differential methylation of a single CpG site in the CD95 ligand promoter affects gene activity and correlates with invasiveness of glioma cells"
5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
September 25-28, 2019
Paris, France
Representatives:
David Richards, Ph.D., Head of Immunology
Julian Sefrin, Ph.D., Senior Scientist Immunology
Poster Presentation: "The hexavalent CD40 agonist HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies"
ESMO 2019
September 27 - October 1, 2019
Barcelona, Spain
Representative: Andriy Krendyukov, M.D., MBA, VP Medical Affairs
ESMO Colloquium: Recurrent glioblastoma management: Challenges and opportunities
September 30, 6:30-8:00 pm, Salamanca Auditorium (Hall 3)
This educational activity is provided by ESMO and supported by Apogenix AG.
4th Biennial World Summit of Brain Tumour Patient Advocates
October 9-12, 2019
Bethesda, MD, USA
Representative: Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment
Festival of Biologics
October 15-17, 2019
Basel, Switzerland
Representatives:
Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering
Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization
Presentation on October 16, 12:05 pm:
"HERA-CD40L: A unique hexavalent CD40 agonist for cancer immunotherapy"
ISPOR Europe 2019
November 2-6, 2019
Copenhagen, Denmark
Representative: Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment
Poster Presentation on November 4, 3:30-7:00 pm (Poster Author Discussion Hour: 6:00-7:00 pm):
"Therapeutic Benefit of Orphan Drugs in Oncology: Evidence at the Point of European Marketing Authorisation"
BIO-Europe 2019
November 11-13, 2019
Hamburg, Germany
Representatives:
Juergen Gamer, Ph.D., VP Business Development
Niclas Kneisel, Ph.D., Alliance Manager
11th Annual PEGS Europe
November 18-22, 2019
Lisbon, Portugal
Representatives:
Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering
Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization
Presentation by Dr. Hill on November 22, 2:35 pm:
"HERA-GITRL: A Unique Hexavalent GITR Agonist for Cancer Immunotherapy"
SNO 2019 Annual Meeting
November 22-24, 2019
Phoenix, AZ, USA
Representative: Juergen Gamer, Ph.D., VP Business Development
19th Annual PepTalk
January 20-24, 2020
San Diego, CA, USA
Representative: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering